|
Market Closed -
Sao Paulo
22:38:37 05/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 78.80 BRL | -8.22% |
|
-8.61% | +0.72% |
| 09-28 | UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating | MT |
| 09-23 | TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating | MT |
| Market Cap | 128B 637B 114B 106B 96.52B 182B 12,290B 183B 1,282B 499B 6,273B 479B 469B 20,163B | P/E 2026 * |
51.7x | P/E 2027 * | 27.3x |
|---|---|---|---|---|---|
| Enterprise Value | 122B 609B 109B 101B 92.33B 174B 11,757B 175B 1,226B 477B 6,000B 458B 448B 19,288B | EV / Sales 2026 * |
9.21x | EV / Sales 2027 * | 8.11x |
| Free-Float |
99.79% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Vertex Pharmaceuticals Incorporated
| 1 day | -8.22% | ||
| 1 week | -8.61% | ||
| Current month | -8.22% | ||
| 1 month | -10.19% | ||
| 3 months | -8.70% | ||
| 6 months | +11.16% | ||
| Current year | +0.72% |
| 1 week | 77.53 |  | 85.86 |
| 1 month | 77.53 | | 86.22 |
| Current year | 65.18 | | 89.01 |
| 1 year | 65.18 | | 89.01 |
| 3 years | 52.29 | | 93.56 |
| 5 years | 30.91 | | 93.56 |
| 10 years | 20.29 | | 93.56 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 01/04/2020 | |
Charles Wagner
DFI | Director of Finance/CFO | 57 | 10/04/2019 |
Sean Daughtry
CTO | Chief Tech/Sci/R&D Officer | - | 01/03/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Bruce Sachs
BRD | Director/Board Member | 66 | 01/01/1998 |
Jeffrey Leiden
CHM | Chairman | 70 | 01/05/2012 |
Sangeeta Bhatia
BRD | Director/Board Member | 57 | 18/06/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.22% | -8.61% | - | - | 128B | |
| +0.02% | -3.52% | +36.11% | +111.11% | 1,019B | |
| -1.21% | -6.99% | +34.08% | +60.96% | 610B | |
| +1.12% | -0.20% | +13.62% | +80.24% | 470B | |
| -3.30% | -6.15% | +56.45% | +34.69% | 344B | |
| +1.15% | +1.06% | +22.40% | +42.28% | 336B | |
| +0.89% | -2.83% | +11.06% | +32.95% | 266B | |
| +2.41% | -3.13% | -5.40% | +10.03% | 241B | |
| -0.01% | -3.62% | +35.28% | +52.02% | 218B | |
| -0.08% | -4.98% | +28.34% | +93.61% | 179B | |
| Average | -0.14% | -3.63% | +25.77% | +57.54% | 409.2B | |
| Weighted average by Cap. | +0.49% | -3.51% | +28.60% | +68.83% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 13.25B 66.09B 11.82B 11.01B 10.02B 18.87B 1,276B 19.01B 133B 51.76B 651B 49.73B 48.66B 2,093B | 14.55B 72.59B 12.98B 12.09B 11.01B 20.73B 1,401B 20.88B 146B 56.85B 715B 54.62B 53.45B 2,299B |
| Net income | 2.54B 12.65B 2.26B 2.11B 1.92B 3.61B 244B 3.64B 25.46B 9.91B 125B 9.52B 9.31B 401B | 4.84B 24.13B 4.31B 4.02B 3.66B 6.89B 466B 6.94B 48.57B 18.9B 238B 18.16B 17.76B 764B |
| Net Debt | -5.54B -27.65B -4.94B -4.61B -4.19B -7.89B -534B -7.95B -55.66B -21.65B -272B -20.81B -20.36B -876B | -9.58B -47.79B -8.55B -7.96B -7.25B -13.64B -923B -13.75B -96.2B -37.43B -471B -35.96B -35.18B -1,513B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/10/26 | R$78.80 | -8.22% | 695 |
| 29/09/26 | R$85.86 | -0.42% | 611 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VRTX Stock
- VRTX34 Stock
Select your edition
All financial news and data tailored to specific country editions
